Clasp Therapeutics is positioning itself at the forefront of the immuno-oncology field, as illustrated by its slogan: "Pioneering precise immuno-oncology with next-gen T cell engagers targeting specific tumor mutations." Focused on harnessing next-generation T cell engagers (TCEs), the company aims to combat hard-to-treat cancers by targeting tumor-specific oncogenic driver mutations. Their approach is innovative in its dual focus on personalizing treatment based on the patient's immune system and the specific tumor genetics.
Founded in 2020 and officially launched in March 2024, Clasp Therapeutics builds on extensive academic research from Johns Hopkins University. It holds a dual base in Cambridge, MA and Rockville, MD. The company's cutting-edge developments have garnered significant backing, evidenced by a substantial $150.00M Series A investment led by University Ventures. Further endorsement comes from notable backers such as Catalio Capital Management, Third Rock Ventures, and Novo Holdings.
Harpoon Therapeutics